Mostrar el registro sencillo del ítem
Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection
dc.contributor.author | Lala, Anuradha et al. | |
dc.date.accessioned | 2020-07-07T13:44:56Z | |
dc.date.available | 2020-07-07T13:44:56Z | |
dc.date.issued | 2020-06-08 | |
dc.identifier.uri | doi.org/10.1016/j.jacc.2020.06.007 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/1973 | |
dc.description.abstract | Background: The degree of myocardial injury, as reflected by troponin elevation, and associated outcomes among US hospitalized patients with Coronavirus Disease 2019 (COVID-19) are unknown. Objectives: To describe the degree of myocardial injury and associated outcomes in a large hospitalized cohort with laboratory-confirmed COVID-19. Methods: Patients with COVID-19 admitted to one of five Mount Sinai Health System hospitals in New York City between February 27th and April 12th, 2020 with troponin-I (normal value <0.03ng/mL) measured within 24 hours of admission were included (n=2,736). Demographics, medical history, admission labs, and outcomes were captured from the hospitals’ EHR. Results: The median age was 66.4 years, with 59.6% men. Cardiovascular disease (CVD) including coronary artery disease, atrial fibrillation, and heart failure, was more prevalent in patients with higher troponin concentrations, as were hypertension and diabetes. A total of 506 (18.5%) patients died during hospitalization. In all, 985 (36%) patients had elevated troponin concentrations. After adjusting for disease severity and relevant clinical factors, even small amounts of myocardial injury (e.g. troponin I 0.03-0.09ng/mL, n=455, 16.6%) were significantly associated with death (adjusted HR: 1.75, 95% CI 1.37-2.24; P<0.001) while greater amounts (e.g. troponin I>0.09 ng/dL, n=530, 19.4%) were significantly associated with higher risk (adjusted HR 3.03, 95% CI 2.42-3.80; P<0.001). Conclusions: Myocardial injury is prevalent among patients hospitalized with COVID-19 however troponin concentrations were generally present at low levels. Patients with CVD are more likely to have myocardial injury than patients without CVD. Troponin elevation among patients hospitalized with COVID-19 is associated with higher risk of mortality. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Myocardial Contusions | en_US |
dc.subject | Cardiomyopathies | en_US |
dc.subject | Troponin | en_US |
dc.subject | Hospitalization | en_US |
dc.subject | Patients | en_US |
dc.subject | Coronavirus Infections | en_US |
dc.title | Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection | en_US |
eihealth.country | Global (WHO/OMS) | en_US |
eihealth.category | Epidemiology and epidemiological studies | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Slow Spread / Reducir la Dispersión | en_US |
dc.relation.ispartofjournal | JACC | en_US |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |